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- 
Acute pulmonary embolism wiih infarction cm delay wgedl) 
needed heart twwplantation sod iocrease the p+stopgratwo pui- 
manmy complications. Few data are available conc~rntog pwrno~ 
nary embotiidae in the pediatric patient with end-stage rongs- 
tive he*rt failure. Stxty.two consecuttve pediatric pjrientr 
nwatttng hart transp!pnbtion were monitored for evid%rw of 
acute pulmonary embolism. *cute pulmonary infarction wlli 
documented by veolilationqwfuston scan. pulmonary ar&r% 
ohy or oatho!& examination in six oallents. Thr rrevatence 
palmnary emholism with infaretin. 
No sign&-ant differewe in age at the time oi transplantation 
watuatton, duration of wnpestive heart failure, preanm of 
eardii arrhytbmtas or degree of cardiac dysfuoction was sfa 
Cardiac disease is a major risk factor for thrombwmbolic 
events in adult paiients (l-3). The mortality rate associnted 
with systemic or pulmonary embolism has beeo reported (4) 
to be as high as 38% in patients with dilated cardiomyopathy. 
For the patient with end-stage congestive heart failure. acute 
pulmonary infarction secondary to embolization can delay 
urgeody needed heart transplantation and increase the post- 
operative pulmonary complication< IS-S). Anticoagulant 
theraov is currentlv recommended for the prevention of an 
embo& event in the adult patient who is ai risk 11.9-I I). 
A few reoorts 112-15) have characterized the incidence of 
systemic embolic phenomena in the pediatric patienr with 
poorventricularfunctioo, but nod&are published conccrn- 
ing pulmonary cmbolization. This study II describes Ihe 
occurrence of acute pulmonary embolism with infarction IO a 
group of children evaluated for hean transplantation at our 
institution, and 2) addresses issues of prevenlion and man- 
agclllc”t. 
Methods 
Study patientr. Pediatric patients referred for evaluation 
for heart transplantation from May 1984 until October 1989 
were observed for evidence of BCUR pulmonary embolism 
wi!h infarction on admission ano while awaiting Iransplan- 
tation. Sixly-nw consecutive patient3 who were referred LO 
our tr~nsplaraation ccntcr because af intractable heart fait- 
we or symptomatic inoperable congenital hran disease. or 
both. were included in the study. Thirty-six patients had 
dilated cardiomyopathy, 20 had congenital heart disease. 5 
had restrictive cardiomyopathy and I had a large left ven- 
tricular tumor. 
The clinical history of all patients referred for evaluation 
war reviewed for the occorrcnce of rhromboembolic events. 
Five patients had a history of systemic embolism before 
evaluation for transplantation; three of the five had a docu- 
mented cerebrovascular accident and Iwo had evidence of a 
tran+nt ischemic attack. One patient wdh a transient ixh- 
emit attack also had pulmonary infarction treated by pulmo- 
nary resection 2 years before referral for transplantation. 
Clinical evatuattoo. Acute puhnonary embolism with in- 
farwon was demonstrated by several means including ven- 
t&moo-perfusion scan. puh&nary angiography. direct visu- 
alization or oatholoeic examination of Ihe luws. The clinical 
I 
course ofthe patients with and without an embolic event was 
analyzed with respect to diagnosis, age at the time of 
evaluation, duration of congestive heart failure. cardiac 
rhythm. cardiac function, anticoagulant therapy and pres- 
ence of echacardiographically demonstrated intracardiac 
Ihrombus. To identify additional patients who might have 
been at increased risk for an embolic event. autopsy or 
explanted hearts were examined for the presence oi intra- 
cardiac thrombus in 41 pa&Is. 
Staliatics. Statistical analysis was performed with the use 
of Student’s I test and cht-square analysis. 
RWdtS 
Embolic events (Table I). In five patients the diagnosis of 
acute pulmonary infarction was suspected on the basis of 
clinical history and chest roentgenographic findings during 
the evaluation period or while awaiting heart tnnsplanta- 
lion. In another patient. the diagnosis was made by direct 
visualization of a small wedge of mdmonarv infarction at the 
time of tnnrplanration. Thicardiac diagndsis. age. mode of 
presentation, chest X-ray localization of pulmonary infarc. 
lion. method of documcnta!ioa and outcome of the six 
patients arc summarized in Table I. 
Four patients had a ventilation-perfusion scan performed: 
in two, the study was diagnostic of acute pulmonary embo- 
lism and in two. the diagnosis was indeterminate because of 
matched ventilation-perfusion defects. Pulmonary embolism 
was :ocumented in the latter by selective pulmonary angi- 
ogmphy. Rtient 6 could not undergo di&nostic &dies 
because of his unstable hemodvnamic condition. but multi- 
ple areas of pulmonary iofar&n were demonstrated at 
autopsy. No episodes of systemic thromboembolism were 
documented during the study period. 
Prevalence. The prevs’ence of pulmonary infarction tiif- 
fered by diagnosis in the 6? patients referred for evaluation 
for heart transplantation. Of the 36 patients with the diagno- 
sis of dilated cardiomyopathy. 5 (14%) developed acute 
pulmonary infarction. One (5%) of the 20 patients with 
congenilal heart disease had documented pulmonary infare- 
[ion. This patient had undergone repair of corrected trans- 
position of the great arteries. ventricular reptal defect and 
pulmonary stenosis with placement of an artificial conduit to 
the pulmonary artery and closure of the ventricular septal 
defect. The five vatients with restrictive cardiomvoaathv 
and the one pat& with a large left ventricular turn& d/d nit 
have acute pulmonary embolism. 
Age, duration of illncsr and cardiac rhythm. There was no 
significant difference in the age of the six patients who 
developed acute pulmonary infarction (mean t SD i3.3 * 
4.8 years) and that of the 56 patients who did not (IO.3 + 6.5 
years). The median duration ofillness was similar for the two 
groups (13.5 and I2 months, respectively). Two patients had 
a history of tachyarrhythmias before the development of 
acute oulmonarv embolism: one had recent con&on from 
atrial ~brilla&lflurter and the other had automatic atrial 
tachycardia controlled by antiarrthylhmic therapy for 3 
months. The remaining four patients had normal sinus 
rhythm before acute pulmonary infarction. Eleven of the 56 
patienls without acute pulmonary embolism also had rhythm 
disturbances: 2 had atrial tachycardia. 4 had atrial fibrilla- 
tionlflutter and 5 had complete heart block. 
Ventriculsr tunction (Table 2). Both groups of patients 
exhibited markedly decreased left ventricular function. 
However, no significant difference in cardiac index, M-mode 
echocardiographically determined percent fractional short- 
ening and ejection fraction deremdned by gated pool nuclear 
angiography was seen between the groups with and without 
pulmonary infarction. 
Two of the six patients with pulmonary embolism had 
clinical signs of right heart lailure. including hepatomegaly. 
peripheral edema and ascites. Four of these patients had 
Table 1. IA “en,ric”lar F”“ctlo” I” six Paricnh patrenrc urrh congenital heart disease. None of the patient< 
Pallenlr Wllh PaliC”l, Wllh”“l wrth rcstrrctwe cardiomyopathy or the patient with the left 
Pvrmonary Pulmanar? ventricular tumor had edher intracardiac thrombun or an 
ErntaiKnl Emborsm embolic phenomenon. 
Cardiac ,wlex ,tirerilmin pr, rn~r 2 I T 1.6 a.7 T / I Patient outcome. Two of rhe six parienrs who developed 
FnEtlnnal Ihorrenlne O.-mod? II) i 811 ril T ioc’r acute pulmonary infarction are alive after heart transplanta- 
right ventricular dilation seen on echocardiography and fue 
had Doppler evidence of tricuspid regurgitation. 
.4ntkoagulant therapy. Three patients were receiving an- 
ttcoagtdant therapy before the onret of acute pulmonary 
infarction: aspirin in one. aspirin and disopyramide in an- 
other and low dose subcutaneous hcparin in the third. None 
or the patients who developed acute pulmonary embobrm 
were treated with anticwgulation with warfarin or innave- 
nous henarin. 
Of the patients who did not have pulmona: y embolism. 5 
were taking aspirin with or without disopyramide. I was 
taking subcutaneous heparin and 20 were taking either 
warfarin or intravenous hepann for anticoagulanon. Eleven 
of the 20 in the latter group received anticoagulant therapy 
after intracardiac thmrnbus was noted on ech&diography. 
The five patients who had a thromboembolic event before 
evrduation underwent anticcapulant therapy and none of 
these developed acute pulmonary embolism while awaitrng 
transplantation. There were no bleeding episodes associated 
with anticoagulant therapy. 
ItttmcarrJiae lhrnmbm. All six patients who developed 
pulmonary embolism underwent two-dimensional echocar- 
diogmphy rl month before clinical acute puhueilary infarc- 
tion. intracardiac thrombus was seen on echocardiography 
in two of these six patients tin the right atrium in one and in 
the left ventricle in the otherl: it was not seen in the other 
four. Thirteen (23%) of the 56 patients wnhout pulmonary 
infarction had intracardiac thrombus demonsirated on echo- 
cardiography. The thrombus was located rn the left ventricle 
in six patients, the left atrium in one patient. the right atrium 
in three patients and the right ver.tricle in three. Statistical 
analysis of these data revealed no rignPcant difference in the 
incidence of echocardiographically demrw:rated intracar- 
diac thmmbus between the groups with and without acute 
pulmonary embolism. 
Risk of thromboembalism. Among the 62 patients. 5 had 
a history of a thromboembolic event. 6 had pulmonary 
embolism during the study period. I? had intracardiac 
thrombus seen on echocardiography and I patient had 
thrombus identified at pathologic examination of the ex- 
planted heart. Thus, 39% of the patients in the study were 
found to have experienced an emholic event or could he 
considered at risk for such an occurrence on the basis of 
intracardiac thrombus. This includes I9 (53%) of the 36 
patients with dilated cardiomyopathy and 5 (25%) of the 20 
lion. A srnalt wedge of pulmonary infarction was resected 
intraoperatrvely in a 6.5 year old boy in whom the diagnosis 
was not suspected. The-second pattent. a 9 year old boy. 
underwent ,uccsssful hesn transplantanon 3 months after 
the dragnosis of acute pulrnonury infarction. He had received 
antroaphr therapy with intrarenous heparin followed by 
oral uarfarin for a total of 2 months. Nomral pulmonary 
vascular resistance was documertted before transplantation. 
Neither of these two patients had further pulmonary se- 
quelae attributable to then pulmonary embolism. 
Four patrents with documented pulmonary infarctron dred 
while receiving anticoagulant therapy. Each had been placed 
on the active heart transplant recipient waiting lis! and ~rere 
inactivated because of the diagnosis of acute pulmonary 
infarction. Three of lhese children died of congestive heart 
failure at 8.38 and 39 days. respectively, after the diagnosis 
of infarctron. The fourth child died of sudden ventricular 
fibrillation 41 days after anticoagulant therapy was insti- 
tuted. 
Discussion 
lnttacardiac lhrombm and dilPted cardiomyopathy. In- 
tracardiac thrombus fomtanon among patients with end- 
stage congestive heart failure IS mnrated by blood stasis in 
the poorly functioning ventricle. In a series of 120 adult 
pruients studied at necropsy with idiopathic dilated cardio- 
myopathy. right- or left-sided rhmmbus or a mural endocar- 
dial plaque was seen in iO3 (86%) (161. Using a decision 
analysis model. Tsevat et al. (4) reported the risk for 
systemic and pulmonary emholization in dihued cardiomy- 
opathy to be 4% and S%/year. respectively, with a case- 
fatality rate of 3n% for systemic embolization and 38% for 
pulmonary embolization. 
Pre~entton of inteaeardiic thrombus. Although no ran- 
domired trials have been conducted. evidence suggests that 
ine incidence of thromhwmholic events in dilated cardiomy- 
opathy can be decreased with the use of either warfarirr or 
intravenous heparin. Fuster et al. (II reported an occurrence 
of four embolic events/lOO patient-year3 of exposure in 
patients not treated with an anticoagulant agent and no 
embolic events in those receiving and anticoagulant therapy. 
In another study (9) of 38 patients with dilated cardiomyop- 
athy, oral anticoagulant therapy for a median period of 39 
weeks resulted in no lhromhoemhalic events. Seventeen of 
these patients had systemic or pulmonary embolism before 
initiation of anticoagulant therapy. According to many work- 
ers (1.9-l I), standard therapy for the prevention of throm- 
boembolic events includes anticoagulant therapy in the adult 
patient with dilated cardiomyopathy. 
Risk of thrnmhwmholism in pediatric patients. In this 
study, pediatric patients wtth dilated cardiomyopathy and 
low cardiac Output were found to be at risk for thromboem- 
holic events. Among patients with congenital heart disease. 
only one child had pulmonary embolism and this may have 
been related to the presence of a right ventricular to pulmo- 
nary artery porcine valved conduit. However, 4 of the 
remaining 19 patents had intracardiac thromhus demott- 
strated echocardmgraphically or pathologically. Thus. 81 this 
time. no conclusion can be made regarding the relative risk 
of thrumbnemholism in patients with congenital heart dis- 
ease and poor ventricular function. No specific clinical risk 
factor for acute pulmonary embclism was identified. Patient 
age. duration of illness and left ventricular function were 
similar for both groups. Two of the six patients with pulmo- 
nary embolism had a history of atrial tachyarrhythmia. hut a 
similar percent of nonaffected children also hed arrhythmias. 
This l&ding does not Imply that arrhythmias are not an 
initiating factor in embolic phenomena. Indeed. such a 
relation is well documented. Anticoagulation may have 
prevented the patients with arrhythmias in our study from 
experiencing thrombaemholic eventr. 
Echocardiagraphic evidence of tbrombus did not emerge 
as a statistically signiticant risk factor for acute pulmonary 
embolism. This is possibly a result of the limitations of 
two-dimensiomd echocardiography in detecting mural 
plaque or smzll thrombi. These Sndiags undcrscox tbc 
importance of measures to prevent cmholic events. even in 
patients without intracardiac thrombus demonstrated echo- 
cardiographically. 
Pulmonary infarction and heart tran~plsntation. Al- 
thcugh most centers consider acute pulmonary infarction to 
be a contraindication to heart transplantation. successful 
transplantation has been described Ln patients with acute 
pulmonary infarction. Y~unn et al. (7) described eight pa- 
iients with clinical and roent&nogra.phic evidence Of p&o- 
nary infarction who underwent transplantation. These au- 
thors do not state whether or how long pretransplantation 
anticoagulant therapy was administered. All received pulmo- 
nary physiotherapy and antibiotic and anticoagulant therapy 
postoperatively. In four of the eight patients, the infarction 
resolved without surgical intervention. The remaining four 
patients develooed intrathoracic infection as a result of 
tofnrction: one died and three required a late thoracic 
%&al procedure; prolonged (39 to 99 days) chest drainage 
was needed. Cavarocchi et al. (8) recently reported on two 
patients who underwent successful transplantation within 4 
days ofthe development ofacute pulmonary embolism. Both 
pati:nts developed lung abscess, empyema and a hron- 
chopleural fistula after transplantation; these were treated 
surgically by lobectomy and latissimus dorsi muscle Rap 
placement in addition to prolonged hospitalization for anti- 
biotic therapy. Although these Iwo patients survived, the 
authors (8) conclude that “preoperative pulmonary emholi 
should remain a strong relative contraindication for heart 
transplantation.” 
The mortality and morhiditv associated with acute WI- 
monary infarct& were signif;cant in this series. All six 
patients with acute infarction had been accepted as candi- 
dates for heart transplantation. but surgery was delayed until 
the acute process could he resolved in five. Four of these five 
patients died within 6 weeks of the diagnosis of infarction 
without undergoing transplantation. Although the post- 
operative management of pulmonary infection can he com- 
plicated and prolonged, the reported survival of patients 
undergoing transplantation during the acute phase of pulmo- 
nary embolism may indicate that a more aggressive approach 
to transplantation could result in a better cmtcome in these 
critically ill children. Two patients with acute pulmonary 
embolism were able to undergo successful transplantation, 
one with pulmonary wedge resection at the time of diagnosis 
and one after maintenance on inotropic suppon during 2 
months ‘3f anticoagulant therapy. 
Conclusions. Anticoagulation is standard therapy in p+ 
diatric patients with atrial fibrillation; however, many clini- 
cians are reluctant to initiate anticoagulant therapy in chil- 
dren who do not have this specific indication. The risk and 
morbidity of thromboembolic events in this series justify 
extensive measttres to prevent the formation of inlracardiac 
thrombus. In addition, although none of the patients in this 
series had clinical evidence of venous thrombosis, this 
potential factor in the origin of pulmonary embolism can also 
bc diminished by anticoagal&n. Careful monitoring of 
anticoagulant therapy to maintain the therapeutic prothram- 
bin time between I.3 to 1.5 timer the control value results in 
minimal risk of blwding (17). It appears that the potential 
benefits from anticoagulation far outweigh the risk of cam. 
plications in the pediatric patient with poor ventricular 
function awaiting heart transplantation. In our series, 8% of 
patients referred for transplantation had already experienced 
a thromhaembolic event before referral. On this basis, it 
seems reasonable to broaden the indications for anticoagw 
lation to include pediatric patients with severe cardiomyop 
athy sarly in the course of the disease, even before heart 
transplantation is consi< -ei to he the only recourse. 

